Following a world-first approval in Japan, AstraZeneca and Daiichi Sankyo’s second antibody-drug conjugate has crossed the ...
The approval is based on findings from the phase 3, multicenter, open-label, randomized TROPION-Breast01 trial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback